Palette Life Sciences Revenue and Competitors

Location

#6186

Growjo Ranking

Estimated Revenue & Valuation

  • Palette Life Sciences's estimated annual revenue is currently $31.9M per year.(i)
  • Palette Life Sciences's estimated revenue per employee is $251,000

Employee Data

  • Palette Life Sciences has 127 Employees.(i)
  • Palette Life Sciences grew their employee count by 4% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$19.1M76-3%N/AN/A
#2
$8M32-6%N/AN/A
#3
$5M20-9%N/AN/A
#4
$8.5M346%N/AN/A
#5
$5.3M21-9%N/AN/A
#6
$49.7M1980%N/AN/A
#7
$12M48N/AN/AN/A
#8
$8.5M3421%N/AN/A
#9
$30.1M12022%N/AN/A
#10
$56.8M181-1%$199.1MN/A
Add Company

Palette Life Sciences is a fully-integrated medical device company focused on providing a wide range of products and services that improve the quality of life for patients. Led by experienced healthcare executives, the initial company strategy is to transform applications of existing technologies to bring forward novel solutions for underserved conditions. Our portfolio of products focuses on treating conditions in urology/urogynecology disorders, colorectal conditions, radiotherapy, and interventional oncology procedures. We are a passionate team of individuals who enjoy the thrill of building a company whose culture is one of curiosity, compassion and drive. Looking for like-minded staff that has a complementary experience to add to the team. Our superior benefits package is proof positive that we care about our people. Deflux® - the only FDA-approved injectable treatment of vesicoureteral reflux (VUR), a malformation of the urinary bladder that affects 1% of children worldwide. VUR can cause severe infections of the urinary tract and lead to irreversible kidney damage. Solesta® - the only FDA-approved injectable treatment for fecal incontinence, which is also cleared for commercialization in Europe. Fecal incontinence is a debilitating health problem afflicting about 2% of people worldwide with four times more prevalent in women than men. Barrigel®* - a biodegradable injectable treatment for protection of the rectal wall when treating prostate cancer with radiation. The product is approved in Europe and will be further developed for future market introduction in the US. Palette Life Sciences is headquartered in Stockholm, Sweden, with offices in Santa Barbara, California and Dallas, Texas. Learn more at palettelifesciences.com and pharmanest.se. Deflux®, Solesta®, Barrigel®, Restylane®, and NASHA™ are registered trademarks. *In the US, this product is considered investigational and not available for commercial sale in the US.

keywords:N/A

N/A

Total Funding

127

Number of Employees

$31.9M

Revenue (est)

4%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Palette Life Sciences News

2022-04-17 - Absorbable Tissue Spacer Market Growth 2022-2029| Key ...

Boston Scientific; BioProtect; Palette Life Sciences; Morita; Biocomposites Limited; CR Bard. Absorbable Tissue Spacer Market Breakdown by Type:.

2022-03-22 - Palette Life Sciences Receives Favorable Post Approval ...

Palette Life Sciences is a fully integrated life sciences company. Palette Life Sciences' products improve patient outcomes in urology and...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$12.7M12728%N/A
#2
$18.1M129-6%$26.7M
#3
$7.5M13521%N/A
#4
$15M1463%N/A
#5
$52.6M1470%N/A

Palette Life Sciences Executives


NameTitle
Travis GayChief Commercial Officer (CCO)
Ole MikkelsenChief Operating Officer
Per LangöPresident and Chief Executive Officer
Hank CoursonExecutive Vice President and Chief Financial Officer
Per LangoeCEO
James LeechVP of Strategy & Corporate Development
Jeff LewisVice President, US Sales
Per LangöPresident and Chief Executive Officer
Hank CoursonExecutive Vice President and Chief Financial Officer
Amy AshtonVP of Global Human Resources
Richard LowVP of Marketing